Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Agricultureread more
A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
"It troubles me that the most important political office in the world is becoming the face of racism and exclusion," Kaeser said in a Twitter post.Politicsread more
Silver's rally could be losing its shine after the precious metal reached its year-to-date high, futures experts warn.Futures Nowread more
Some 40% of Americans would struggle to come up with even $400 to pay for an emergency expense. Just how are so many Americans so short on cash? Blame debt.Personal Financeread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
There needs to be more transparency in drug pricing — including looking at the middlemen — but when it comes to the controversy about Mylan's pricing of its EpiPen, the company still has a lot of questions to answer, Sen. Charles "Chuck" Grassley, R-Iowa, said Thursday.
"Transparency and things of that nature I think are very, very important but in this particular instance we've got one company with a monopoly on the product going up more than 400 percent," the chairman of the Senate Judiciary Committee said in an interview with CNBC's "Power Lunch. "
The drug, used to counteract a potentially fatal allergic reaction, has a retail cost of more than $600. On Thursday, the company announced it increased rebates to many consumers.
Mylan CEO Heather Bresch told CNBC on Thursday that she too was "frustrated" over the EpiPen furor, noting that the price reflects a system where the drug goes through middlemen before it gets to patients.
She also said she has reached out to Grassley to talk about the issue, in response to a letter the senator sent on Monday requesting information about the sharp price increases.
Grassley said that someone from the company called his office, but he said he wanted to get all of the questions he posed in his letter answered before having a meeting.
"I'm going to wait until then and read on paper their justification for these … gigantic increases that they've had that I think are unjustified."
The senator also sent a letter this week to the Food and Drug Administration, asking for information about its approval process and other steps for alternatives to the EpiPen.
"Competition will draw down the price and we want to know whether that process can be speeded up to get competition to the market," he told CNBC. "I think one of the reasons Mylan had the guts to move this price up so rapidly is because they do have a monopoly, and about 40 percent of their clientele is Medicaid, so they can cheat the taxpayers as much as they're cheating the individual families."
Sen. Amy Klobuchar, D-Minn., has also called for Mylan to explain its price hikes. She told CNBC on Thursday that she has spoken to Bresch and that the two will meet.
She also said she appreciated that the company has done something to ease the burden on consumers.
However, "I don't think that fixes a systemic problem we're seeing across pharmaceuticals where the top 10 drugs in America, four of them have had over 100 percent increases in just the last four years," she said in an interview with "Closing Bell. "
Klobuchar, whose daughter has a severe nut allergy and carries the EpiPen, has also called for the Federal Trade Commission to investigate Mylan for possible antitrust violations.
She said also she has a bill pending with Sen. John McCain, R-Ariz., that would allow cheaper, safer drugs into the U.S. from Canada to create competition.
"My wish is that there would be a generic alternative, a competitor" to the EpiPen, Klobuchar said.
— CNBC's Dan Mangan contributed to this report.